Modeling the effectiveness of initial management strategies for ductal carcinoma in situ

Journal of the National Cancer Institute

Volumn 105, Issue 11, 2013, Pages 774-781

  Soeteman, Djøra I ^a   Stout, Natasha K ^b   Ozanne, Elissa M ^c   Greenberg, Caprice ^d   Hassett, Michael J ^b   Schrag, Deborah ^b   Punglia, Rinaa S ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST RECONSTRUCTION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SIMULATION; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECURRENCE RISK;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE EFFECTIVENESS RESEARCH; COMPUTER SIMULATION; DECISION MAKING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAMMAPLASTY; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT PARTICIPATION; RADIOTHERAPY, ADJUVANT; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84878846134     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt096     Document Type: Article

References (32)

1. Sumner WE 3rd, Koniaris LG, Snell SE, et al. Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol. 2007;14(5):1638-1643. (Pubitemid 46791002)
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. http://seer.cancer.gov/csr/1975-2008/.
3. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381-3387. (Pubitemid 46638893)
4. Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536-543. (Pubitemid 44167203)
5. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400-418. (Pubitemid 32762083)
6. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95-102. (Pubitemid 36831018)
7. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer. 1993;71(8): 2507-2514. (Pubitemid 23100484)
8. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-488.
9. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011:12(1):21-29.
10. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627-637.
11. Solin LJ, Gray R, Baehner FL, et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Paper presented at San Antonio Breast Cancer Symposium; December 2011; San Antonio, TX. Abstract S4-6.
12. Briggs AH, Sculpher MJ, Claxton K. Decision Modeling for Health Economic Evaluation. New York: Oxford University Press; 2006.
13. Barton P, Johanputra P, Wilson J, Bryan S, Burls A. The use of modeling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004;8:1-104.
14. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85(3):616-628. (Pubitemid 29075283)
15. Lee LA, Silverstein MJ, Chung CT, et al. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg. 2006;192(4):416-419. (Pubitemid 44344203)
16. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program. http://www.seer.cancer.gov/about/. Accessed April 2, 2011.
17. Fong J, Kurniawan ED, Rose AK, et al. Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone. Ann Surg Oncol. 2011;18(13):3778-3784.
18. Greenberg CC, Schneider EC, Lipsitz SR, et al. Do variations in provider discussions explain socioeconomic disparities in postmastectomy breast reconstruction? J Am Coll Surg. 2008;206(4):605-615.
19. Schonberg MA, Marcantonio ER, Ngo L, Silliman RA, McCarthy EP. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol. 2011;29(12):1570-1577.
20. Olivotto IA, Truong PT, Speers CH. Staging reclassification affects breast cancer survival. J Clin Oncol. 2003;21(23):4467-4468.
21. Rosenberg MA. Competing risks to breast cancer mortality. J Natl Cancer Inst. 2006(36):15-19.
22. Group EBCTCG. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-177.
23. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106. (Pubitemid 41797643)
24. Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. Tradeoffs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. J Clin Oncol. 1996;14(1):70-77. (Pubitemid 26019999)
25. McCormick B. RTOG 9804: a prospective randomized trial for "good risk" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). Paper presented at the 2012 ASCO Annual Meeting; June 2012; Chicago, IL.
26. Halasz LM, Sreedhara M, Chen JH, et al. Improved outcomes of breastconserving therapy for patients with ductal carcinoma in situ. Int J Radiat Oncol. 2012;82(4):e581-e586.
27. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268-73.
28. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6): 443-448. (Pubitemid 38443647)
29. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007;101(3):335-347. (Pubitemid 46169888)
30. Smith BD, Haffty BG, Buchholz TA, et al. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst. 2006;98(18):1302-1310. (Pubitemid 44538160)
31. Yen TW, Kuerer HM, Ottesen RA, et al. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol. 2007;25(22):3251-3258. (Pubitemid 47325609)
32. Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: Institute of Medicine; 2001.